This mechanistic integration, supported by molecular, metabolic, and bioinformatic evidence, underscores the translational potential of Hes + ADR combination therapy in overcoming chemoresistance and eliciting a durable antitumor immune response in ovarian cancer. Here, RRBP1 is linked to ovarian carcinoma.